Eisai Co.,Ltd. Q1 FY2027 earnings call

• 3L Core Product Performance and Updates

  • LENVIMA: Sustained demand growth (especially in the U.S.) and foreign exchange tailwinds drove 16% year-on-year revenue growth. It holds top U.S. market share across multiple indicated cancer types, reaches ~620,000 patients in 83 countries 11 years post-launch, and a new indication supplemental application has an FDA PDUFA action date of October 4, 2026.
  • DAYVIGO: Achieved 38% year-on-year revenue growth across all regions, holds the #1 market share in Japan's dual orexin receptor antagonist segment, and new approval applications were recently submitted in the U.K. and Europe, bringing total approved markets to 29.
  • LEQEMBI: Delivered strong underlying real-demand growth of 64% year-on-year after adjusting for one-time prior-year impacts, holds the leading share of Early Alzheimer's Disease (AD) treated patients in the U.S., and is approved for Early AD in 53 countries. The FDA recently approved the IQLIK subcutaneous auto-injector formulation for initiation treatment, with launch planned for late August 2025. IQLIK enables eligible patients to self-administer treatment at home after two clinic doses, reducing patient, caregiver, and healthcare system burden; real-world evidence presented at AAIC 2026 confirms high treatment retention (86.6% overall, 78.9% for patients treated over 18 months) and a consistent safety profile aligned with trial data. Eisai is prioritizing expansion of blood-based biomarkers (BBM) for AD diagnosis to reduce patient burden and increase diagnostic capacity, with BBM use expected to rise to 50% of all A-beta confirmatory testing by FY2028, from 15% in FY2025.

• Pipeline and Long-Term Strategic Direction

  • AD Drug Discovery: Eisai is pursuing a long-term vision of "making AD a curable disease" by targeting the full AD continuum of amyloid, tau, and neurodegeneration. Next-generation tau-targeting drug etalanetug recently reported positive Phase I biomarker data demonstrating dose-dependent reduction of target tau biomarkers in cerebrospinal fluid and plasma, with Phase II top-line data expected in FY2027. LEQEMBI is currently in a Phase III AHEAD3-45 trial testing pre-symptomatic AD intervention, with data expected in FY2028. The long-term goal is to combine amyloid control (LEQEMBI), tau propagation suppression (etalanetug), and neurodegeneration intervention to prevent AD onset and progression.
  • Orexin Platform: Leveraging DAYVIGO's success in treating insomnia, Eisai is developing ledasorexton, an orexin 2 receptor agonist for treating excessive daytime sleepiness in narcolepsy (type 1 and type 2). Phase I data demonstrated efficacy and a good safety profile, with Phase II top-line data expected by the end of FY2026. Long-term, the platform aims to expand into broader brain function regulation affecting cognition, behavior, and social participation, with exploratory research ongoing into next-generation compounds and new indications.
  • Oncology Pipeline: Additional LENVIMA indication expansion and combination therapy trials are ongoing, with a PDUFA action date for the LENVIMA + WELIREG combination expected in October 2026, alongside regulatory filings and pipeline milestones for other oncology assets.

• Operational Profit Milestone: Eisai achieved its first-ever quarterly commercial profit for LEQEMBI in Q1 FY2026 (when excluding LEQEMBI R&D expenses), meeting an incremental full-year target ahead of schedule, driven by strong sales growth and disciplined cost allocation.

Eisai's core business is its Pharmaceutical segment, which generated total Q1 FY2026 revenue of 230.9 billion yen, a 16% year-on-year increase, and accounted for 98.5% of the company's total consolidated revenue of 234.3 billion yen. Within the Pharmaceutical segment, the three key 3L products (LENVIMA, DAYVIGO, LEQEMBI) accounted for the majority of segment revenue: LENVIMA generated 97.3 billion yen in Q1 revenue (41.5% of total consolidated revenue, up 16% year-on-year), DAYVIGO generated 18.9 billion yen (8.1% of total consolidated revenue, up 38% year-on-year), and LEQEMBI generated 29.3 billion yen (12.5% of total consolidated revenue, up 27% year-on-year, or 64% after adjusting for the prior-year Chinese distributor stockpiling impact). Total consolidated Q1 revenue was 234.3 billion yen, up 15.6% year-on-year. Total consolidated operating profit was 24.7 billion yen, up 19.2% year-on-year; core operating profit was 24.7 billion yen (up 13.9% year-on-year), and net profit for the period was 18.2 billion yen (up 26% year-on-year).

• Eisai reaffirmed its full-year FY2026 financial guidance, noting that Q1 results (both revenue and operating profit) exceeded internal forecasts even after adjusting for positive foreign exchange impacts, putting the company on steady track to meet full-year targets.
• Full-year product revenue guidance remains unchanged: LENVIMA at 345 billion yen, DAYVIGO at 73.5 billion yen, and LEQEMBI at 143.5 billion yen.
• Management maintains the full-year target of achieving commercial profitability for LEQEMBI (excluding R&D expenses) in FY2026, with Q1 results confirming the company is on track to meet this goal.
• Key upcoming pipeline milestones confirmed: IQLIK approval in Japan expected in Q2 FY2026; ledasorexton Phase II top-line data and E2025 biomarker data expected in FY2026; etalanetug Phase II top-line data in sporadic AD expected in FY2027; AHEAD3-45 and tau next-gen study data expected in FY2028.

No material new operational risks or failures were discussed during the earnings call. Management noted that the main uncertainties relate to the pace of BBM diagnostic adoption, the speed of insurance reimbursement expansion for LEQEMBI IQLIK across global markets, and the success of ongoing late-stage pipeline trials, none of which were framed as immediate material downside risks to the full-year guidance.

Q: Q1 results came in ahead of plan, with a lower-than-expected cost of sales ratio. What factors drove this better-than-expected performance, and what is the impact of foreign exchange? / A: Both revenue (driven by 3L product growth) and operating profit exceeded Q1 plans, even after adjusting for positive foreign exchange impacts. The lower cost of sales ratio stems from reduced per-unit production costs for LEQEMBI and DAYVIGO, as well as a stronger-than-expected contribution from LENVIMA, which has an inherently low cost of sales ratio. The weaker yen provided an 18.9 billion yen positive impact on revenue and a 1.38 billion yen positive impact on operating profit, as the majority of both revenues and costs are foreign currency denominated, limiting the net operating profit impact. Overall, the company considers Q1 a strong steady start to the full year.

Q: What is the outlook for Medicare reimbursement for the newly approved IQLIK LEQEMBI formulation, what is the pricing strategy, and when will IQLIK start contributing to revenue? / A: IQLIK uses the same BLA approval number as the existing IV formulation, so the existing Medicare reimbursement framework for LEQEMBI is expected to apply to the new subcutaneous formulation. Full formulary listing for both initiation and maintenance IQLIK is expected by 2027. Pricing was set to achieve total medical cost parity with IV LEQEMBI: the higher per-vial price of IQLIK reflects the added convenience of home administration, while eliminating patient co-payment differences compared to IV when factoring out infusion-related administration costs. Commercial launch is scheduled for late August 2026, when sales will begin to be recorded, though some providers have already started prescribing IQLIK ahead of full launch. The company expects IQLIK convenience will drive faster new patient initiation and long-term treatment retention.

Q: How is Eisai competing with Eli Lilly's Kisunla in the U.S. AD market, and how successful are conversion efforts for patients who completed fixed-duration Kisunla treatment? / A: Current external data estimates new patient market share is roughly 50-50 between LEQEMBI and Kisunla, though external data often undercounts LEQEMBI's prescribing in large integrated delivery networks. Eisai has already observed conversions of patients who completed fixed-duration Kisunla treatment to LEQEMBI maintenance therapy in clinical practice, which is permitted per LEQEMBI's label. The company expects the recent approval of convenient at-home IQLIK, paired with strong real-world evidence of long-term LEQEMBI safety and retention, will expand its competitive advantage and market share going forward.

Q: Is it correct that IQLIK will have higher profitability per patient than IV LEQEMBI, and will LEQEMBI's overall profitability improve as IQLIK adoption grows? / A: Yes, this understanding is correct. As IQLIK's share of total LEQEMBI volume grows, the overall cost of sales ratio for LEQEMBI as a whole will improve, leading to higher profitability for the product line.